Anifrolumab: Long-term Impact on LLDAS and Remission in Lupus Patients – Results from TULIP Trials
Learn how the TULIP trials demonstrated that anifrolumab significantly improves rates of lupus low disease activity state (LLDAS) and remission in SLE patients.
Anifrolumab is one of the only two biologic treatments approved for patients with moderate to severe SLE. This study investigates the long-term benefits of adding anifrolumab to standard therapy for SLE patients.
A recent post hoc analysis of the TULIP-1 and TULIP-2 trials, followed by a long-term extension study, evaluated the effects of anifrolumab, a monoclonal antibody, on lupus low disease activity state (LLDAS) and remission in patients with moderate to severe systemic lupus erythematosus (SLE).
Key Findings
-
Anifrolumab Increases LLDAS and Remission Rates: Anifrolumab significantly improved the likelihood of achieving LLDAS and remission compared to placebo.
-
Sustained Benefits: Patients receiving anifrolumab were able to sustain these states over a longer period, indicating the potential of the treatment to improve long-term disease control.
Implications for SLE Treatment
These findings suggest that anifrolumab, in combination with standard therapy, offers an effective treatment option for patients with SLE, improving their chances of sustained remission and better disease management.
